Eli Lilly & Co header image

Eli Lilly & Co

LLY

Equity

ISIN null / Valor 947556

New York Stock Exchange, Inc (2026-03-25)
USD 916.31+1.47%

Eli Lilly & Co
UMushroom community rating:

star star star star star
4.18 36 votes No rating yet
NegativeNeutralPositive

About company

Eli Lilly & Co, headquartered in Indianapolis, is a global pharmaceutical company with a significant presence in the healthcare sector. Known for its research, development, and commercialization of pharmaceutical products, Eli Lilly focuses on a wide range of therapeutic areas including but not limited to oncology, diabetes, neurodegeneration, and immunology. The company has recently announced results from a pioneering study of lebrikizumab, a treatment specifically designed for individuals with skin of color suffering from moderate-to-severe atopic dermatitis, also known as eczema. This highlights Eli Lilly's commitment to addressing diverse medical needs and expanding its portfolio to include treatments tailored for specific demographic groups. The company's efforts in innovation and targeted research underscore its role in advancing medical treatments and improving patient outcomes across various disease states.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

7.50%1Y
173%3Y
400%5Y

Performance

42.8%1Y
34.6%3Y
32.1%5Y

Volatility

Market cap

864408 M

Market cap (USD)

Daily traded volume (Shares)

2,177,748

Daily traded volume (Shares)

1 day high/low

779.59 / 771.02

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.18

36 votes
Performance:
starstarstarstarstar
4.16
Innovation:
starstarstarstarstar
4.28
Society:
starstarstarstarstar
4.17
Nature:
starstarstarstarstar
4.02
Mael Caparelli
Switzerland, 22 Mar 2026
star star star star star
L
Gabriele Saponara Teutonico
Switzerland, 22 Mar 2026
star star star star star
.
Laxsijan Selvaratnam
Switzerland, 22 Mar 2026
star star star star star
👍🏽

EQUITIES OF THE SAME SECTOR

DXC Technology Company
DXC Technology Company DXC Technology Company Valor: 35991811
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.36%USD 12.01
BioNTech SE
BioNTech SE BioNTech SE Valor: 50030055
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.26%USD 88.77
MKS Instruments Inc
MKS Instruments Inc MKS Instruments Inc Valor: 616689
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.05%USD 243.68
Nebius Group N.V.
Nebius Group N.V. Nebius Group N.V. Valor: 12955842
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.16%USD 115.09
Rapid7 Inc
Rapid7 Inc Rapid7 Inc Valor: 28570046
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.93%USD 5.60
Progress Software Corp
Progress Software Corp Progress Software Corp Valor: 963966
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.97%USD 27.33
GoDaddy Inc
GoDaddy Inc GoDaddy Inc Valor: 24674951
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.58%USD 81.58
Editas Medicine Inc
Editas Medicine Inc Editas Medicine Inc Valor: 30992799
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.11%USD 2.32
Lightspeed Commerce Inc
Lightspeed Commerce Inc Lightspeed Commerce Inc Valor: 112970662
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.83%CAD 12.19
BlackBerry Ltd
BlackBerry Ltd BlackBerry Ltd Valor: 21892856
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.79%CAD 4.54